万邦德医药控股集团股份有限公司 投资者关系活动记录表 编号：20221122 | --- | --- | --- | |---------------------|--------------------------------------------|-------------------------------------------------------------------------------| | | | | | | ☑ 特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 （ ） | | | | 东吴证券：朱国广 | | | 参与单位名称及 | 财通资管：冯雪云 | | | 人员姓名 | 富安达基金：许睿 | | | | 汐泰投资：杨容瑄 | | | 时间 | 2022 年11月 22 日 公司会议室 | | | 地点 | | | | 上市公司接待人 | 董事长、总经理：赵守明 董事会秘书：刘同科 | | | 员姓名 | 证券事务代表：江建 | | | | 一 ...

Group 1: Company Overview - The company has transformed from traditional aluminum processing and non-ferrous metal trading to a focus on pharmaceutical manufacturing and medical devices since 2017 [1] - Wanbangde Pharmaceutical Group is a high-tech enterprise specializing in the R&D, production, and sales of modern Chinese medicine and chemical raw materials [1] - The core product, Ginkgo Biloba Drop Pills, has independent intellectual property rights and is a national second-level protected Chinese medicine variety [1] Group 2: Product Development and Innovation - The company established the first domestic collaborative innovation alliance for Ginkgo Biloba Drop Pills with over ten institutions, including Chinese universities and hospitals [2] - The leading product, Shikangjian, was developed in the 1980s and has received multiple patents in China, the US, Japan, and the EU [2] - The company has integrated raw material and formulation production, enhancing its competitive edge in the generic drug market [2] Group 3: Market Performance and Financials - In Q1 2021, the pharmaceutical segment's revenue grew by 14% compared to the same period last year [3] - The company has expanded its syringe production capacity to 1 billion units per year, with 7 production lines already operational [3][5] - The company has secured a bid for 23.708 million Chlorpromazine tablets in the third batch of national drug centralized procurement [4] Group 4: Challenges and Strategic Responses - The company has faced increased demand for syringes due to the pandemic, leading to an expansion of production lines [3][5] - The average price increase of raw materials in the pharmaceutical sector has been kept within 2%, with the company managing to pass some costs onto downstream customers [4][5] - The company has ceased its aluminum processing business as of March 2021, focusing solely on pharmaceuticals and medical devices [4]

万邦德医药控股集团股份有限公司 投资者关系活动记录表 编号：20210604 | --- | --- | --- | |---------------------|--------------------------------------|--------------------------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | | 媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | 国海证券：许睿 | | | 参与单位名称及 | 长江证券：陈琪 | | | 人员姓名 | 西南证券：黄宇 | | | 时间 | 2021年6月4 日 | | | | 公司会议室 | | | 地点 | 董事长、总经理：赵守明 | | | 上市公司接待人 | 董事会秘书：刘同科 | | | 员姓名 | 证券事务代表：江建 | | | | 一、公司情况介绍： | | | ...

Company Overview - The company has undergone a transformation from traditional aluminum processing and non-ferrous metal trading to a focus on pharmaceutical manufacturing and medical devices since 2017 [1] - Wanbangde Pharmaceutical Group is a high-tech enterprise specializing in the R&D, production, and sales of modern Chinese medicine, chemical raw materials, and their formulations [1] - The company has a diverse product portfolio, particularly in cardiovascular and neurological medications, and is one of the domestic leaders in terms of drug types and approvals [1] Core Products - The core product, Ginkgo Biloba Drop Pills, is based on German standards and has independent intellectual property rights, classified as a national secondary protected Chinese medicine [1] - The company has developed the first-in-class drug Huperzine A, which has received patents in China, the US, Japan, and the EU [2] - The injection of Huperzine A was successfully launched in 2018, with ongoing clinical trials for controlled-release tablets [2] Market Position and Sales - Ginkgo Biloba Drop Pills hold approximately 18% market share in domestic medical institutions, with a market size of around 3 billion [2] - The sales of Huperzine A injection were about 100 million in 2021, with an expected increase to 160,000 units this year [3] - The company aims to cover 1,000 top-tier hospitals in the next three years as part of its national sales network expansion [3] Future Plans - By 2025, the company plans to achieve an annual output value of 5 billion across its three main production bases: raw materials, formulations, and medical devices [3] - The revenue composition is expected to be approximately one-third from traditional Chinese medicine, chemical medicine, and medical devices [3] - The company is focusing on international market expansion, particularly in the raw materials sector, while maintaining a strong domestic presence [3]

万邦德医药控股集团股份有限公司 投资者关系活动记录表 编号：20220925 | --- | --- | --- | |-------------------------|---------------------------------------|------------------------------------------------------------------------------| | | | | | | ☑ 特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 东吴证券：朱国广、向潇 | | | | 2022年9月25 日 | | | 时间 | 公司会议室 | | | 地点 | 董事长、总经理：赵守明 | | | 上市公司接待人 员姓名 | 董事会秘书：刘同科 证券事务代表：江建 | | | | | | | | | | | | 一、公司情况介绍： | | | | 1. 产业转型升级： ...

万邦德医药控股集团股份有限公司 投资者关系活动记录表 编号：20221027 | --- | --- | --- | |---------------------|----------------------------------|----------------------------------------------------------------------------| | | | | | | □特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | ☑ 其他 | （三季报业绩电话交流会） | | 参与单位名称及 | 详见附件 | | | 人员姓名 | | | | | 2022年10月27 日 | | | 时间 | 电话交流会 | | | 地点 | 董事长、总经理：赵守明 | | | | 董事会秘书：刘同科 | | | | 制药财务总监：王天放 | | | 上市公司接待人 | | | | 员姓名 | 制药销售副总：马健 | | | | 证券事务代表：江建 一、公司 2022 ...

万邦德医药控股集团股份有限公司 投资者关系活动记录表 编号：20221028 | --- | --- | --- | |---------------------|----------------------------------|----------------------------------------------------------------------------| | | | | | | □特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | ☑ 其他 | （三季报业绩电话交流会） | | 参与单位名称及 | 详见附件 | | | 人员姓名 | | | | | 2022年10月28 日 | | | 时间 | 电话交流会 | | | 地点 | 董事长、总经理：赵守明 | | | | 董事会秘书：刘同科 | | | | 制药财务总监：王天放 | | | 上市公司接待人 | | | | 员姓名 | 制药销售副总：马健 | | | | 证券事务代表：江建 一、公司 2022 ...

万邦德医药控股集团股份有限公司 2022 年第三季度报告 证券代码：002082 证券简称：万邦德 公告编号：2022-042 万邦德医药控股集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 万邦德医药控股集团股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 期增减 | | 上年同期增减 | | 营业收入（元） | 452,463,321.26 | 23 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥731,172,957.40, a decrease of 21.27% compared to ¥928,668,326.21 in the same period last year[23]. - The net profit attributable to shareholders was ¥58,095,240.03, down 48.25% from ¥112,253,691.84 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥46,309,465.11, a decline of 46.12% compared to ¥85,941,786.57 in the previous year[23]. - The basic earnings per share decreased by 50.00% to ¥0.09 from ¥0.18 in the same period last year[23]. - The company reported a net cash flow from operating activities of -¥249,613,445.42, worsening by 108.57% compared to -¥119,678,340.56 in the previous year[23]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-over-year growth of 20%[61]. - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 25% driven by new product launches and market expansion strategies[61]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-over-year growth of 20%[62]. - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 25% driven by new product launches and market expansion strategies[62]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2022, representing a 15% year-over-year growth[117]. - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 10% to 15%[117]. Segment Performance - The pharmaceutical manufacturing segment achieved revenue of 547.84 million yuan, a year-on-year increase of 35.63%, with a net profit attributable to shareholders of 95.63 million yuan, up 1.21% year-on-year[31]. - The medical device segment reported revenue of 184.95 million yuan, a year-on-year decrease of 9.51%, with a net loss attributable to shareholders of 16.65 million yuan, down 89.04% year-on-year[31]. - The South African business segment generated revenue of 134.42 million yuan, a year-on-year increase of 1.10%, indicating a gradual recovery as pandemic control measures are relaxed[31]. - Revenue from the pharmaceutical manufacturing segment was CNY 380,988,864.26, accounting for 52.11% of total revenue, down 4.74% year-on-year[69]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,032,395,457.05, a decrease of 7.75% from ¥4,371,377,020.86 at the end of the previous year[23]. - The company’s total assets included CNY 587,438,104.73 in cash, representing 14.57% of total assets, down from 20.86% last year[73]. - The company’s total liabilities included CNY 638,124,922.78 in short-term loans, which accounted for 15.82% of total liabilities, an increase from 13.05% last year[73]. - The total liabilities decreased to CNY 2,032,000,000.00 from CNY 2,200,000,000.00, indicating a reduction of about 7.7%[171]. Research and Development - The company is currently developing new products, including the controlled-release version of Huperzine A, which has completed Phase I clinical trials and is in the implementation of Phase II clinical plans[37]. - The company has received approval for the consistency evaluation of the drug Benzyl Alcohol Injection in February 2022[37]. - The company has completed laboratory research for Cimetidine tablets and plans to conduct large-scale production in August 2022[38]. - The company is actively pursuing the development of innovative drugs and generic drugs, with several products undergoing consistency evaluation and clinical trials[38]. - The company plans to invest 200 million RMB in R&D for new technologies over the next two years[61]. - The company is investing 100 million CNY in R&D for new technologies aimed at improving production efficiency[117]. Market Expansion - The company is focusing on expanding its market presence in Southern Africa through the import and distribution of advanced medical equipment[42]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by the end of 2023[61]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 25% increase in market penetration by the end of 2023[115]. - The company is undergoing a strategic transformation to adapt to future asset integration needs, adjusting its asset structure based on financial data from the end of 2017[116]. Environmental Compliance - The company has established a dedicated environmental protection department and emergency response team to comply with national regulations and mitigate risks[88]. - The company reported that all monitored pollutants from its subsidiaries were within the regulatory limits, indicating compliance with environmental standards[97]. - The company processed wastewater and emissions in accordance with municipal standards, with no exceedances reported for key pollutants such as COD and ammonia nitrogen[97]. - The company has effectively managed hazardous waste disposal, ensuring that all metrics remain within regulatory limits[99]. Shareholder and Governance - The company emphasizes the protection of minority shareholders' rights and timely information disclosure[104]. - The company has committed to a three-year dividend return plan for 2021-2023, ensuring shareholder returns[125]. - The company has established an independent financial department and management system to ensure proper financial governance[110]. - The company guarantees that its business operations are independent from other enterprises controlled by the promoters, maintaining the ability to operate autonomously in the market[116]. Strategic Initiatives - The company aims to enhance its management efficiency and core competitiveness by upgrading manufacturing equipment and strengthening key technology R&D[54]. - The company is committed to talent development, focusing on building a strong management and R&D team to maintain competitive vitality[55]. - The company is actively addressing market competition risks by ensuring business integration and enhancing market competitiveness across various sectors[87]. - The company has established partnerships with three leading hospitals to enhance clinical trials and product validation processes[62].

Financial Performance - The company's revenue for Q1 2022 was ¥332,630,226.54, a decrease of 42.85% compared to ¥582,004,755.24 in the same period last year[3] - Net profit attributable to shareholders was ¥24,786,291.16, down 10.10% from ¥27,572,053.71 year-on-year[3] - The net profit excluding non-recurring gains and losses increased by 51.91% to ¥21,136,499.31 from ¥13,914,168.13 in the previous year[3] - Total operating revenue for Q1 2022 was CNY 332,630,226.54, a decrease from CNY 582,004,755.24 in the previous period[17] - Net profit for Q1 2022 was CNY 21,717,056.80, compared to CNY 27,131,157.80 in the same period last year[19] - Earnings attributable to the parent company for Q1 2022 were CNY 24,786,291.16, a decrease from CNY 27,572,053.71 in the previous year[19] - Comprehensive income for Q1 2022 was CNY 44,210,324.73, an increase from CNY 24,306,076.47 in the previous year[19] Cash Flow - The net cash flow from operating activities improved by 52.91%, reaching -¥86,915,507.07 compared to -¥184,585,297.73 in the same period last year[3] - The company reported a total cash flow from operating activities of CNY 4,218,398.34 for Q1 2022[19] - Cash inflow from operating activities totaled 419,489,821.15, down 31.2% from 610,759,549.83 in the prior period[21] - Cash outflow from operating activities was 506,405,328.22, a decrease of 36.4% compared to 795,344,847.56 in the previous period[21] - The net cash flow from investing activities was -62,692,040.49, a significant decline from 531,654,347.83 in the last period[22] - Cash inflow from investing activities was 9,103,070.12, a drop of 98.7% from 680,471,465.44 in the previous period[22] - Cash outflow from investing activities totaled 71,795,110.61, down 51.8% from 148,817,117.61 in the prior period[22] - The net cash flow from financing activities was -60,407,800.65, an improvement from -457,494,235.96 in the previous period[22] - Cash inflow from financing activities was 115,048,915.12, a decrease of 65.9% compared to 337,556,526.78 in the last period[22] - Cash outflow from financing activities was 175,456,715.77, down 77.9% from 795,050,762.74 in the previous period[22] - The ending cash and cash equivalents balance was 696,808,622.34, an increase from 459,266,203.64 in the prior period[22] Assets and Liabilities - Total assets decreased by 4.57% to ¥4,171,668,326.64 from ¥4,371,377,020.86 at the end of the previous year[3] - The company’s total liabilities increased to CNY 2.22 billion from CNY 2.15 billion, reflecting a rise of about 3.2%[15] - Total liabilities as of Q1 2022 amounted to CNY 1,390,802,992.05, down from CNY 1,626,694,346.84 in the previous period[16] - Total equity as of Q1 2022 was CNY 2,780,865,334.59, compared to CNY 2,744,682,674.02 in the previous period[16] - The company’s total equity attributable to shareholders increased by 1.11% to ¥2,627,246,483.33 from ¥2,598,357,643.63 at the end of the previous year[4] Operating Costs and Expenses - The company reported a significant reduction in operating costs, which fell by 57.61% to ¥167,154,617.63 from ¥394,280,743.62 year-on-year[8] - Total operating costs for Q1 2022 were CNY 311,988,803.46, down from CNY 564,433,824.80 in the previous period[17] - Research and development expenses decreased by 35.20% to ¥14,046,918.09 from ¥21,678,678.82 in the previous year[8] - Research and development expenses for Q1 2022 were CNY 14,046,918.09, down from CNY 21,678,678.82 in the previous year[17] Strategic Developments - The company has divested from aluminum processing businesses, which significantly impacted revenue comparisons with the previous year[4] - The company’s subsidiary successfully passed the FDA 510(k) review for its medical surgical masks and self-destructing syringes, enhancing its competitiveness in the international market[12] - The company plans to accelerate the market promotion of its isopropyl phenol injection, leveraging its production advantages in raw materials and formulations[11] Other Income - The company received government subsidies amounting to ¥1,187,312.01 during the quarter, contributing to a 959.36% increase in other income[8]